Skip to content

Study · Randomized controlled trial · 2016

10 results

Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.

Leder BZ, Tsai JN, Neer RM, Uihlein AV, Wallace PM, Burnett-Bowie SA

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry15 Feb 2016Cited by 22 (Europe PMC)

PMID26900146 (opens in a new tab)DOI10.1016/j.jocd.2016.01.004 (opens in a new tab)PepBankPUB-26900146
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, total hip BMD response over 3% occurred in 92% with combination therapy versus 53% with denosumab.

    In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased the frequency of total hip response over 3%.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD response over 3%: addition to denosumab
    Study

    n: not reported in source

    Comparator
    denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneous · 24 moAs given in this study (human).

    Measurements

    Proportion with total hip BMD increase >3%
    92%
    combination group
    Proportion with total hip BMD increase >3%
    53%
    denosumab group

    Source sentences

    Summary
    Over 24 mo, TH BMD increased by >3% in 36%, 53%, and 92% of women in the teriparatide, denosumab, and combination groups, respectively, and by >6% in 11%, 17%, and 50% in the teriparatide, denosumab, and combination groups, respectively (p < 0.01 for all comparisons vs combination).
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, total hip BMD response over 6% occurred in 50% with combination therapy versus 17% with denosumab.

    In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased the frequency of total hip response over 6%.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD response over 6%: addition to denosumab
    Study

    n: not reported in source

    Comparator
    denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneous · 24 moAs given in this study (human).

    Measurements

    Proportion with total hip BMD increase >6%
    50%
    combination group
    Proportion with total hip BMD increase >6%
    17%
    denosumab group

    Source sentences

    Summary
    Over 24 mo, TH BMD increased by >3% in 36%, 53%, and 92% of women in the teriparatide, denosumab, and combination groups, respectively, and by >6% in 11%, 17%, and 50% in the teriparatide, denosumab, and combination groups, respectively (p < 0.01 for all comparisons vs combination).
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, femoral neck response rates followed the total hip pattern, favoring combination therapy over denosumab.

    In plain wordsIn women with osteoporosis, femoral neck response favored adding teriparatide to denosumab, as at the total hip.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck response: addition to denosumab
    Study

    n: not reported in source

    Comparator
    denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneous · 24 moAs given in this study (human).

    Source sentences

    Summary
    FN response rates were similar to TH.
    5 context sentences
    Summary · context
    Over 24 mo, TH BMD increased by >3% in 36%, 53%, and 92% of women in the teriparatide, denosumab, and combination groups, respectively, and by >6% in 11%, 17%, and 50% in the teriparatide, denosumab, and combination groups, respectively (p < 0.01 for all comparisons vs combination).
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, lumbar spine response over 3% was 100% with combination therapy versus 93% with denosumab, without significant difference.

    In plain wordsIn women with osteoporosis, adding teriparatide to denosumab did not significantly change lumbar spine response over 3%.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine response over 3%: addition to denosumab
    Study

    n: not reported in source

    Comparator
    denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneous · 24 moAs given in this study (human).

    Measurements

    Proportion with lumbar spine BMD increase >3%
    100%
    combination group
    Proportion with lumbar spine BMD increase >3%
    93%
    denosumab group

    Source sentences

    Summary
    In the LS, BMD increased by >3% in 85%, 93%, and 100% of women in the teriparatide, denosumab, and combination groups, respectively (p = nonsignificant for all comparisons)
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, lumbar spine response over 6% occurred in 100% with combination therapy versus 78% with denosumab.

    In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased the frequency of lumbar spine response over 6%.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine response over 6%: addition to denosumab
    Study

    n: not reported in source

    Comparator
    denosumab alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneous · 24 moAs given in this study (human).

    Measurements

    Proportion with lumbar spine BMD increase >6%
    100%
    combination group
    Proportion with lumbar spine BMD increase >6%
    78%
    denosumab group

    Source sentences

    Summary
    and by >6% in 63%, 78%, and 100% of women in the teriparatide, denosumab, and combination groups, respectively (combination vs teriparatide, p = 0.001; combination vs denosumab, p = 0.016).
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, lumbar spine BMD increased by >3% in 85% with teriparatide versus 93% with denosumab, without significant difference.

    In plain wordsIn women with osteoporosis, lumbar spine response over 3% did not differ significantly between teriparatide and denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine BMD response over 3% versus denosumab
    Study

    n: not reported in source

    Comparator
    denosumab
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneous · 24 moAs given in this study (human).

    Measurements

    Proportion with lumbar spine BMD increase >3%
    85%
    teriparatide group
    Proportion with lumbar spine BMD increase >3%
    93%
    denosumab group

    Source sentences

    Summary
    In the LS, BMD increased by >3% in 85%, 93%, and 100% of women in the teriparatide, denosumab, and combination groups, respectively (p = nonsignificant for all comparisons)
    2 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In women with osteoporosis, total hip BMD response over 3% occurred in 36% with teriparatide versus 92% with combination therapy.

    In plain wordsIn women with osteoporosis, total hip response over 3% was less frequent with teriparatide than with combination therapy.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTotal hip BMD response over 3%: monotherapy
    Study

    n: not reported in source

    Comparator
    denosumab plus teriparatide
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Proportion with total hip BMD increase >3%
    36%
    teriparatide group
    Proportion with total hip BMD increase >3%
    92%
    combination group

    Source sentences

    Summary
    Over 24 mo, TH BMD increased by >3% in 36%, 53%, and 92% of women in the teriparatide, denosumab, and combination groups, respectively, and by >6% in 11%, 17%, and 50% in the teriparatide, denosumab, and combination groups, respectively (p < 0.01 for all comparisons vs combination).
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In women with osteoporosis, total hip BMD response over 6% occurred in 11% with teriparatide versus 50% with combination therapy.

    In plain wordsIn women with osteoporosis, total hip response over 6% was less frequent with teriparatide than with combination therapy.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTotal hip BMD response over 6%: monotherapy
    Study

    n: not reported in source

    Comparator
    denosumab plus teriparatide
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Proportion with total hip BMD increase >6%
    11%
    teriparatide group
    Proportion with total hip BMD increase >6%
    50%
    combination group

    Source sentences

    Summary
    Over 24 mo, TH BMD increased by >3% in 36%, 53%, and 92% of women in the teriparatide, denosumab, and combination groups, respectively, and by >6% in 11%, 17%, and 50% in the teriparatide, denosumab, and combination groups, respectively (p < 0.01 for all comparisons vs combination).
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In women with osteoporosis, lumbar spine response over 3% was 85% with teriparatide versus 100% with combination therapy, without significant difference.

    In plain wordsIn women with osteoporosis, lumbar spine response over 3% did not differ significantly between teriparatide and combination therapy.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine response over 3%: monotherapy
    Study

    n: not reported in source

    Comparator
    denosumab plus teriparatide
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Proportion with lumbar spine BMD increase >3%
    85%
    teriparatide group
    Proportion with lumbar spine BMD increase >3%
    100%
    combination group

    Source sentences

    Summary
    In the LS, BMD increased by >3% in 85%, 93%, and 100% of women in the teriparatide, denosumab, and combination groups, respectively (p = nonsignificant for all comparisons)
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In women with osteoporosis, lumbar spine response over 6% occurred in 63% with teriparatide versus 100% with combination therapy.

    In plain wordsIn women with osteoporosis, lumbar spine response over 6% was less frequent with teriparatide than with combination therapy.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseLumbar spine response over 6%: monotherapy
    Study

    n: not reported in source

    Comparator
    denosumab plus teriparatide
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Proportion with lumbar spine BMD increase >6%
    63%
    teriparatide group
    Proportion with lumbar spine BMD increase >6%
    100%
    combination group

    Source sentences

    Summary
    and by >6% in 63%, 78%, and 100% of women in the teriparatide, denosumab, and combination groups, respectively (combination vs teriparatide, p = 0.001; combination vs denosumab, p = 0.016).
    4 context sentences
    Summary · context
    In DATA, 94 postmenopausal osteoporotic women (ages 51-91) were randomized to receive teriparatide (20 mcg subcutaneously daily), denosumab (60 mg subcutaneously every 6 mo), or both medications for 24 mo.
    Summary · context
    The 82 subjects who completed all 2-yr treatments were analyzed.
    Summary · context
    Responders were defined as experiencing BMD increases of >3%.
    Summary · context
    An "excellent response" was defined as an increase of >6%.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.